Comparison of the effects of [Phe<sup>1</sup>Ψ(CH<sub>2</sub>‐NH)Gly<sup>2</sup>]Nociceptin (1–13)NH<sub>2</sub> in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptorsHirobumi Okawa, David G. Lambert, Beverley Nicol et al.|British Journal of Pharmacology|1999Cited by 80
Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone‐inducible mammalian expression systemJohn McDonald, David G. Lambert, Tim A. Barnes et al.|British Journal of Pharmacology|2003Cited by 74
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptorsValeria Camarda, David G. Lambert, Jonathan P. Thompson et al.|European Journal of Pharmacology|2004Cited by 59
<i>In vitro</i> and <i>in vivo</i> pharmacological characterization of nociceptin/orphanin <scp>FQ</scp> tetrabranched derivativesA. Rizzi, Girolamo Calò, Davide Malfacini et al.|British Journal of Pharmacology|2014Cited by 33
<i>In vitro</i> and <i>in vivo</i> pharmacological characterization of the novel UT receptor ligand [Pen<sup>5</sup>,<scp>D</scp>Trp<sup>7</sup>,Dab<sup>8</sup>]urotensin II(4–11) (UFP‐803)Valeria Camarda, Girolamo Calò, Martina Spagnol et al.|British Journal of Pharmacology|2005Cited by 32